A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Actinic Keratosis (AK)
In brief
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Key facts
- Study ID
- NCT07318675
- Run by
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- People needed
- 40
- Starts
- 2025-12-25
- Expected to finish
- 2026-03-01
- Last updated by the study team
- 2026-01-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Shanghai Skin Disease Hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.